Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: MacroRisk Analytics/EconomicInvestor
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA's Sanofi Pasteur Announces the European Commission Approval for HexyonTM/Hexacima Vaccine

Monday, 22 Apr 2013 01:00am EDT 

Sanofi SA's Sanofi Pasteur announced that the European Commission approved the Company's pediatric vaccine 6-in-1 HexyonTM/Hexacima (vaccine DTCa-IPV-Hib-HepB) for primo-vaccination and secondary vaccination od children from the age of six weeks. HexyonTM/Hexacima is a 6-in-1 vaccine, 100% liquid, protecting the infants from diphtheria, tetanus, whooping cough, poliomyelitis, hepatitis B and the invasive infections caused by type b Haemophilus influenzae. The new vaccine will be marketed as Hexyon in the Western-Europe countries and as Hexacima in the Eastern-Europe countries. 

Company Quote

0.78 +0.95%
29 Aug 2014